Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology

Understanding Your Diagnosis: Pancreatic Small Cell Neuroendocrine Carcinoma

At a Glance

Pancreatic small cell neuroendocrine carcinoma is a rare, fast-growing cancer that needs confirmation by an experienced specialist and prompt scans, including checks that it did not start in the lungs, so treatment can be planned accurately.

Receiving a diagnosis of Pancreatic Small Cell Neuroendocrine Carcinoma (SC-NEC) can feel overwhelming, especially because it is so rare. You are likely hearing many complex terms for the first time, and the urgency your medical team is showing may be frightening. This page is designed to help you understand exactly what this diagnosis means, how it differs from other pancreatic cancers, and why your next steps are so critical.

Defining Pancreatic SC-NEC

Pancreatic SC-NEC is a type of poorly differentiated cancer, meaning the cells look markedly abnormal or disorganized and do not form the structures typical of normal pancreatic tissue [1][2]. It is a “high-grade” tumor, defined by its aggressive behavior and high proliferation rate (how fast the cells are dividing) [3].

While it shares a name with “small cell lung cancer,” pancreatic SC-NEC is a distinct entity that starts in the pancreas [4]. However, it behaves similarly to small cell cancers in other parts of the body—it grows quickly and often requires a specific type of treatment, typically involving platinum-based chemotherapy [5].

How Rare Is It?

This is one of the rarest forms of pancreatic cancer. To put it in perspective:

  • Neuroendocrine Neoplasms (NENs) make up only a small fraction of all pancreatic cancers.
  • High-grade Neuroendocrine Carcinomas (PanNECs) represent less than 5% of all pancreatic neuroendocrine tumors [6].
  • Small Cell is a specific subtype of PanNEC, making it an exceptionally rare “rare disease” [7].

Because it is so uncommon, many community hospitals may only see one or two cases in a decade. This is why involving a specialized center for a second opinion is strongly advisable.

The Biology of the Tumor

The behavior of SC-NEC is driven by specific genetic mutations that tell the cells to divide without stopping. Scientists have identified several key molecular markers often found in these tumors:

  • TP53 and RB1 Mutations: These are common genetic changes in SC-NEC, although they are not present in every single case [8]. They act like “broken brakes” on a car, allowing cells to grow uncontrollably [1].
  • High Ki-67 Index: The Ki-67 index is a percentage that measures how many cells are currently proliferating. In SC-NEC, this number is high—often exceeding 50% or 80%, though values can vary depending on the biopsy sample and heterogeneity of the tumor [1][3].
  • Neuroendocrine Markers: To confirm the diagnosis, pathologists look for specific proteins such as synaptophysin, chromogranin A, or CD56 [9][10].

Why an Accurate Diagnosis Matters

It is very easy to confuse SC-NEC with other types of pancreatic tumors, such as the more common Pancreatic Ductal Adenocarcinoma (PDAC) or Well-Differentiated Grade 3 Neuroendocrine Tumors (NET G3) [11][12].

This distinction is vital because the treatments are completely different. For example, a G3 NET might be treated with CAPTEM, FOLFOX, or PRRT, while SC-NEC requires intensive systemic chemotherapy [13][14]. An expert pathologist at a high-volume center will use morphology integrated with specialized stains (like Rb and p53) to ensure the diagnosis is correct [15][11].

Immediate Next Steps

The speed and complexity of this diagnosis require a highly coordinated approach, ideally managed by a multidisciplinary team [16][14].

  1. Seek a Specialist Center: Look for a “Center of Excellence” for neuroendocrine tumors or a high-volume pancreatic cancer center. These teams include specialized oncologists and pathologists who have specific experience with high-grade NEC [13]. You can do this concurrently with local care.
  2. Confirm the Primary Site: Because small cell cancer can start in the lungs and spread to the pancreas, doctors must perform thorough clinical correlation and imaging (such as a chest CT) to be certain the cancer originated in the pancreas [4][17].
  3. Comprehensive Imaging: You may need multiple types of scans. While a standard contrast CT or MRI is the foundation for staging, you might also receive an FDG-PET scan, which is often recommended to identify active, high-grade cells [18][19].
  4. Discuss Clinical Trials: Because this is a rare disease, standard treatments are limited. Specialized centers often have access to clinical trials evaluating new combinations of chemotherapy, immunotherapy, or targeted drugs.

The path forward requires rapid action, but you do not have to navigate it alone. Connecting with a specialized team ensures that you are receiving the most accurate diagnosis and the most effective evidence-based care available today [13][14].

Common questions in this guide

What is pancreatic small cell neuroendocrine carcinoma?
Pancreatic small cell neuroendocrine carcinoma is a rare, high-grade cancer that starts in the pancreas and usually grows quickly. Although it can behave like small cell lung cancer, it is a separate disease when the pancreas is the original site.
How do doctors confirm a pancreatic SC-NEC diagnosis?
An experienced pathologist reviews how the cells look and uses specialized tests for neuroendocrine proteins such as synaptophysin, chromogranin A, and CD56. Additional stains and expert review can help distinguish SC-NEC from pancreatic ductal adenocarcinoma and well-differentiated grade 3 neuroendocrine tumors.
What does a high Ki-67 index mean in pancreatic SC-NEC?
The Ki-67 index estimates the percentage of tumor cells that are actively dividing. A high value supports the diagnosis of a fast-growing, high-grade tumor, but the result can vary between biopsy samples because different areas of the tumor may behave differently.
Which scans are used to stage pancreatic small cell neuroendocrine carcinoma?
A contrast-enhanced CT scan or MRI commonly provides the foundation for staging. Doctors may also recommend an FDG-PET scan to identify active high-grade disease, and chest imaging is important to check whether a small cell cancer began in the lungs rather than the pancreas.
Why should I get a second opinion at a specialist center?
This cancer is rare, so a high-volume pancreatic or neuroendocrine tumor center may have more experience reviewing the pathology and coordinating care. A multidisciplinary team can also help with staging, treatment decisions, and access to relevant clinical trials.
What treatment is commonly considered for pancreatic SC-NEC?
Treatment often includes intensive systemic chemotherapy, commonly a platinum-based regimen, because this cancer tends to grow quickly. The exact plan depends on the confirmed diagnosis, stage, overall health, and available clinical trials; investigational combinations may include chemotherapy, immunotherapy, or targeted drugs.

Get notified when new evidence is published on pancreatic small cell neuroendocrine carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (19)
  1. 1

    Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study.

    Hijioka S, Hosoda W, Matsuo K, et al.

    Clinical cancer research : an official journal of the American Association for Cancer Research 2017; (23(16)):4625-4632 doi:10.1158/1078-0432.CCR-16-3135.

    PMID: 28455360
  2. 2

    Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment.

    Zhang MY, He D, Zhang S

    World journal of gastrointestinal oncology 2020; (12(7)):705-718 doi:10.4251/wjgo.v12.i7.705.

    PMID: 32864039
  3. 3

    The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

    Basturk O, Yang Z, Tang LH, et al.

    The American journal of surgical pathology 2015; (39(5)):683-90 doi:10.1097/PAS.0000000000000408.

    PMID: 25723112
  4. 4

    Pancreatic Neuroendocrine Tumors: From Benchside to Surgical Treatment.

    Conzo G, Mongardini FM, Paolicelli M, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(3)) doi:10.3390/medicina62030479.

    PMID: 41901560
  5. 5

    Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3.

    Merola E, Falconi M, Rinke A, et al.

    American journal of surgery 2020; (220(2)):284-289 doi:10.1016/j.amjsurg.2020.03.009.

    PMID: 32209239
  6. 6

    Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.

    Haugvik SP, Kaemmerer D, Gaujoux S, et al.

    Current oncology reports 2016; (18(5)):28 doi:10.1007/s11912-016-0518-9.

    PMID: 26984415
  7. 7

    Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009-2021.

    Stang A, Wellmann I, Holleczek B, et al.

    Cancer epidemiology 2024; (93()):102659 doi:10.1016/j.canep.2024.102659.

    PMID: 39243580
  8. 8

    Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3.

    Konukiewitz B, Jesinghaus M, Steiger K, et al.

    Human pathology 2018; (77()):70-79 doi:10.1016/j.humpath.2018.03.018.

    PMID: 29596894
  9. 9

    Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study.

    Sigel CS, Krauss Silva VW, Reid MD, et al.

    Cancer cytopathology 2018; (126(5)):326-335 doi:10.1002/cncy.21982.

    PMID: 29451738
  10. 10

    [Pancreatic Neuroendocrine Tumor Presenting as Acute Pancreatitis].

    Kim M, Park JM, Lee SJ, et al.

    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi 2018; (71(2)):98-102 doi:10.4166/kjg.2018.71.2.98.

    PMID: 29471608
  11. 11

    A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.

    Tang LH, Basturk O, Sue JJ, Klimstra DS

    The American journal of surgical pathology 2016; (40(9)):1192-202 doi:10.1097/PAS.0000000000000662.

    PMID: 27259015
  12. 12

    Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.

    Taskin OC, Clarke CN, Erkan M, et al.

    Journal of gastrointestinal oncology 2020; (11(3)):548-558 doi:10.21037/jgo.2020.03.07.

    PMID: 32655934
  13. 13

    Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Shah MH, Goldner WS, Benson AB, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(7)):839-868.

    PMID: 34340212
  14. 14

    Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.

    Eads JR, Halfdanarson TR, Asmis T, et al.

    Endocrine-related cancer 2023; (30(8)).

    PMID: 37184955
  15. 15

    Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.

    Sigel CS, Krauss Silva VW, Reid MD, et al.

    Cancer cytopathology 2018; (126(1)):44-53 doi:10.1002/cncy.21934.

    PMID: 29044913
  16. 16

    Diagnostic and prognostic biomarkers for pancreatic neuroendocrine neoplasms.

    Sonnen AF, Verschuur AVD, Brosens LAA

    Pathologie (Heidelberg, Germany) 2024; (45(Suppl 1)):74-82 doi:10.1007/s00292-024-01393-8.

    PMID: 39556246
  17. 17

    Radiological and Histological Correlation in Small Cell Neuroendocrine Carcinoma of the Breast: A Case Report.

    Gharaibeh MM, Elobeid EA, El-Heis MA, et al.

    The American journal of case reports 2021; (22()):e932274 doi:10.12659/AJCR.932274.

    PMID: 34570746
  18. 18

    Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update.

    Prosperi D, Gentiloni Silveri G, Panzuto F, et al.

    Journal of clinical medicine 2022; (11(22)) doi:10.3390/jcm11226836.

    PMID: 36431313
  19. 19

    Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.

    Calabrò D, Argalia G, Ambrosini V

    Diagnostics (Basel, Switzerland) 2020; (10(12)) doi:10.3390/diagnostics10121059.

    PMID: 33297381

This page explains pancreatic small cell neuroendocrine carcinoma for informational purposes only and does not constitute medical advice. Your oncology team and specialist pathologist should interpret your results and recommend care for your situation.

Guide contents pancreatic small cell neuroendocrine carcinoma
Research & Literature
02 Symptoms & Warning Signs of Pancreatic SC-NEC